Overview

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-31
Target enrollment:
Participant gender:
Summary
This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors
Phase:
PHASE1
Details
Lead Sponsor:
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd